POTENTIAL OF MIRNA-183, MIRNA-29B, AND MIRNA-34A COMBINATION AS A NOVEL ADVANCED SENSORINEURAL HEARING LOSS DIAGNOSTIC AND THERAPEUTIC (THERAGNOSTIC) AGENT

Background: Sensorineural hearing loss (SNHL) is a hearing disability that makes up 90% of all hearing loss in general. This condition reduces quality of life and causes lifelong disability. Current diagnostic and therapeutic agents are considered less than optimal and need to be developed further....

Full description

Saved in:
Bibliographic Details
Main Authors: Agyta Hanifa Faiza, Gabriela Valencia Putri Husodho, Anatalya Diah Ayu Kumalasari
Format: Article
Language:English
Published: Faculty of Medicine, Universitas Diponegoro 2025-05-01
Series:Jurnal Kedokteran Diponegoro
Subjects:
Online Access:https://ejournal3.undip.ac.id/index.php/medico/article/view/47640
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850169407513296896
author Agyta Hanifa Faiza
Gabriela Valencia Putri Husodho
Anatalya Diah Ayu Kumalasari
author_facet Agyta Hanifa Faiza
Gabriela Valencia Putri Husodho
Anatalya Diah Ayu Kumalasari
author_sort Agyta Hanifa Faiza
collection DOAJ
description Background: Sensorineural hearing loss (SNHL) is a hearing disability that makes up 90% of all hearing loss in general. This condition reduces quality of life and causes lifelong disability. Current diagnostic and therapeutic agents are considered less than optimal and need to be developed further. MicroRNAs (miRNAs), such as miRNA-34a, miRNA-29b, and miRNA-183, play a role in the pathogenesis of SNHL and thus have potential as specific biomarkers and therapeutic agents. Objective: To open a new perspective regarding the use of diagnostic biomarkers and miRNA therapy as a new step towards the era of personalized medicine in SNHL patients. Methods: This literature review used a non-systematic review method using the search engines PubMed, Science Direct, and ProQuest. Results: Increased expression of miRNA-34a, miRNA-29b, and miRNA-183 causes a decrease in the number of inner hair cells hence causing hearing loss. This means that these miRNAs can be used as biomarkers in the diagnosis of SNHL. Suppression of these miRNAs to certain levels could potentially be a therapy for SNHL, as it showed reduced oxidative stress and apoptosis. Suppression of miRNA-29b expression causes increased proliferation and reduced oxidative stress. However, knock out of miRNA-183 shows disruption in stereociliary bundle development and hair cell maturation hence when using miRNA inhibitors as therapy it is important to take note of dosage. Conclusion: miRNA-34a, miRNA-29b, and miRNA-183 have potential as diagnostic biomarkers and therapeutic agents for SNHL by regulating levels of oxidative stress, apoptosis, and the number of inner hair cells. Utilizing these three miRNAs simultaneously can increase the specificity, sensitivity and effectiveness in the diagnosis and therapy of SNHL.
format Article
id doaj-art-e81fc4fd5fe94b268b37c3cb071ba064
institution OA Journals
issn 2540-8844
language English
publishDate 2025-05-01
publisher Faculty of Medicine, Universitas Diponegoro
record_format Article
series Jurnal Kedokteran Diponegoro
spelling doaj-art-e81fc4fd5fe94b268b37c3cb071ba0642025-08-20T02:20:44ZengFaculty of Medicine, Universitas DiponegoroJurnal Kedokteran Diponegoro2540-88442025-05-0114311212110.14710/dmj.v14i3.4764033904POTENTIAL OF MIRNA-183, MIRNA-29B, AND MIRNA-34A COMBINATION AS A NOVEL ADVANCED SENSORINEURAL HEARING LOSS DIAGNOSTIC AND THERAPEUTIC (THERAGNOSTIC) AGENTAgyta Hanifa Faiza0https://orcid.org/0009-0005-1977-4908Gabriela Valencia Putri Husodho1https://orcid.org/0009-0009-1828-8923Anatalya Diah Ayu Kumalasari2https://orcid.org/0009-0001-8111-3351Undergraduate Program, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia, IndonesiaFaculty of Medicine, Universitas Diponegoro, Jl. Prof. Sudarto, SH, Tembalang, Semarang, Indonesia, IndonesiaUndergraduate Program, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia, IndonesiaBackground: Sensorineural hearing loss (SNHL) is a hearing disability that makes up 90% of all hearing loss in general. This condition reduces quality of life and causes lifelong disability. Current diagnostic and therapeutic agents are considered less than optimal and need to be developed further. MicroRNAs (miRNAs), such as miRNA-34a, miRNA-29b, and miRNA-183, play a role in the pathogenesis of SNHL and thus have potential as specific biomarkers and therapeutic agents. Objective: To open a new perspective regarding the use of diagnostic biomarkers and miRNA therapy as a new step towards the era of personalized medicine in SNHL patients. Methods: This literature review used a non-systematic review method using the search engines PubMed, Science Direct, and ProQuest. Results: Increased expression of miRNA-34a, miRNA-29b, and miRNA-183 causes a decrease in the number of inner hair cells hence causing hearing loss. This means that these miRNAs can be used as biomarkers in the diagnosis of SNHL. Suppression of these miRNAs to certain levels could potentially be a therapy for SNHL, as it showed reduced oxidative stress and apoptosis. Suppression of miRNA-29b expression causes increased proliferation and reduced oxidative stress. However, knock out of miRNA-183 shows disruption in stereociliary bundle development and hair cell maturation hence when using miRNA inhibitors as therapy it is important to take note of dosage. Conclusion: miRNA-34a, miRNA-29b, and miRNA-183 have potential as diagnostic biomarkers and therapeutic agents for SNHL by regulating levels of oxidative stress, apoptosis, and the number of inner hair cells. Utilizing these three miRNAs simultaneously can increase the specificity, sensitivity and effectiveness in the diagnosis and therapy of SNHL.https://ejournal3.undip.ac.id/index.php/medico/article/view/47640mirna-183mirna-29bmirna-34asnhltheragnostic
spellingShingle Agyta Hanifa Faiza
Gabriela Valencia Putri Husodho
Anatalya Diah Ayu Kumalasari
POTENTIAL OF MIRNA-183, MIRNA-29B, AND MIRNA-34A COMBINATION AS A NOVEL ADVANCED SENSORINEURAL HEARING LOSS DIAGNOSTIC AND THERAPEUTIC (THERAGNOSTIC) AGENT
Jurnal Kedokteran Diponegoro
mirna-183
mirna-29b
mirna-34a
snhl
theragnostic
title POTENTIAL OF MIRNA-183, MIRNA-29B, AND MIRNA-34A COMBINATION AS A NOVEL ADVANCED SENSORINEURAL HEARING LOSS DIAGNOSTIC AND THERAPEUTIC (THERAGNOSTIC) AGENT
title_full POTENTIAL OF MIRNA-183, MIRNA-29B, AND MIRNA-34A COMBINATION AS A NOVEL ADVANCED SENSORINEURAL HEARING LOSS DIAGNOSTIC AND THERAPEUTIC (THERAGNOSTIC) AGENT
title_fullStr POTENTIAL OF MIRNA-183, MIRNA-29B, AND MIRNA-34A COMBINATION AS A NOVEL ADVANCED SENSORINEURAL HEARING LOSS DIAGNOSTIC AND THERAPEUTIC (THERAGNOSTIC) AGENT
title_full_unstemmed POTENTIAL OF MIRNA-183, MIRNA-29B, AND MIRNA-34A COMBINATION AS A NOVEL ADVANCED SENSORINEURAL HEARING LOSS DIAGNOSTIC AND THERAPEUTIC (THERAGNOSTIC) AGENT
title_short POTENTIAL OF MIRNA-183, MIRNA-29B, AND MIRNA-34A COMBINATION AS A NOVEL ADVANCED SENSORINEURAL HEARING LOSS DIAGNOSTIC AND THERAPEUTIC (THERAGNOSTIC) AGENT
title_sort potential of mirna 183 mirna 29b and mirna 34a combination as a novel advanced sensorineural hearing loss diagnostic and therapeutic theragnostic agent
topic mirna-183
mirna-29b
mirna-34a
snhl
theragnostic
url https://ejournal3.undip.ac.id/index.php/medico/article/view/47640
work_keys_str_mv AT agytahanifafaiza potentialofmirna183mirna29bandmirna34acombinationasanoveladvancedsensorineuralhearinglossdiagnosticandtherapeutictheragnosticagent
AT gabrielavalenciaputrihusodho potentialofmirna183mirna29bandmirna34acombinationasanoveladvancedsensorineuralhearinglossdiagnosticandtherapeutictheragnosticagent
AT anatalyadiahayukumalasari potentialofmirna183mirna29bandmirna34acombinationasanoveladvancedsensorineuralhearinglossdiagnosticandtherapeutictheragnosticagent